



## 2023 – 2024 ACTRIMS Didactic Series Disclosure Information

As a provider dedicated to independent education and accredited by the ACCME, IPMA must ensure balance, independence, objectivity, scientific rigor, and integrity in all its educational activities. All individuals with potential to influence the content of this program have disclosed all financial relationships that have occurred in the past 24 months with ineligible companies. The disclosures have been reviewed according to policy. All individuals with potential conflicts have been contacted as needed by IPMA staff, and issues of conflict have been discussed, managed, and mitigated. All individuals with the ability to influence the content of this educational activity have no relevant financial relationships with ineligible companies to disclose except for those listed below:

Individual	Role	Disclosure
Brenda Banwell, MD	Faculty	<i>Consultant:</i> Novartis, Roche, GSK, UCB Pharma
Amit Bar-Or, MD, FRCPC	Faculty	<i>Advisory Board:</i> Abata, Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Horizon Therapeutics, Immunic, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sangamo, Sanofi-Genzyme, Viracta <i>Research:</i> Biogen Idec, Roche/Genentech, Merck/EMD Serono, Novartis
Jeffrey Bennett, MD, PhD	Faculty	<i>Advisory Board, Consultant, Research, Speakers Bureau:</i> Alexion Pharmaceuticals; <i>Advisory Board &amp; Consultant:</i> Genentech/Roche, Imcyse, Horizon Therapeutics
Riley Bove, MD, MMSc	Faculty	<i>Research:</i> Biogen, Roche Genentech, Novartis, Eli Lilly; <i>Advisory Board:</i> Alexion, Biogen, EMD Serono, Janssen Novartis, TG Therapeutics
Jeffrey Cohen, MD	Faculty	<i>Consulting:</i> Biogen, Convelo, EMD Serono, Gossamer Bio, Mylan, PSI
Divyanshu Dubey, MD	Faculty	KLHL11 patent licensed as a marker of neurological autoimmunity and testicular germ cell tumor. Patent pending for LUZP4, Cavin-4 and SKOR2 as a marker of neurological autoimmunity. <i>Consultant:</i> UCB, Immunovant, Argenx, Arialys and Astellas. All compensation for consulting activities is paid directly to Mayo Clinic. Received funding from the DOD for germ cell tumor immunoprofiling (CA210208) and inflammatory neuropathy autoantibody identification/validation (PR220430)
Eoin Flanagan, MBBCh	Faculty	<i>Advisory Board:</i> Alexion, Genentech, Horizon Therapeutics, UCB
Sarah Flanagan Wesley, MD, MPH	Faculty	<i>Advisory Board &amp; Research:</i> Novartis
Robert Fox, MD	Faculty	<i>Consultant:</i> AB Science, Biogen, BMS, EMD Serono, Genentech, Genzyme, Greenwich Biosciences, Immunic, Inmune Bio, Janssen, Lilly, Novartis, Sanofi, Siemens, TG Therapeutics; <i>Advisory Board:</i> AB Science, Biogen, Genzyme, Immunic, Janssen, Novartis, Sanofi; <i>Research:</i> Biogen Novartis, Sanofi
Jeffrey M. Gelfand, MD, MAS, FAAN	Faculty	<i>Research:</i> Roche/Genentech, Vigil Neuroscience; <i>Consultant:</i> Arialys, Ventyx Bio
Erin Longbrake, MD, PhD	Planner	<i>Consultant:</i> Bristol Myers Squibb, Genentech, NGM Bio, TG Therapeutics, Janssen, EMD Serono, Genzyme, Biogen <i>Research:</i> Biogen, Genentech
Sona Narula, MD	Faculty	<i>Research:</i> Alexion Pharmaceuticals

Jennifer Orthmann-Murphy, MD	Faculty	<i>Research:</i> Vigil Neurosciences <i>Consultant:</i> Vigil Neuroscience, NovoGlia
------------------------------	---------	--